A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).

Binghe Xu,Wei Li,Qingyuan Zhang,Shao Zhi-min,Wang Xiao-jia,Huiping Li,Tao Sun,Yongmei Yin,Hong Zheng,Hong Zhang,Tiffanie Chan,Guiyuan Lei,Eleonora Restuccia

A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).

2019

Binghe Xu
Wei Li
Qingyuan Zhang
Shao Zhi-min
Wang Xiao-jia
Huiping Li
Tao Sun
Yongmei Yin
Hong Zheng
Hong Zhang
Tiffanie Chan
Guiyuan Lei
Eleonora Restuccia

1026Background: In CLEOPATRA (NCT00567190), adding P to H + D significantly improved progression-free and overall survival (PFS/OS) v Pla + H + D in patients (pts) with previously untreated HER2-po...

Keywords:

Placebo
Trastuzumab
Puffin
Pathology
Oncology
Pertuzumab
Metastatic breast cancer
Docetaxel
Internal medicine
Medicine
in patient
double blind

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations